ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 16.17 BATS BZX Real-Time Price As of 2:31pm ET |  +0.22 / +1.38%Today’s Change | 14.51 Today|||52-Week Range 41.20 | -46.30% Year-to-Date |
Latest ACAD News | Press Releases
| Steven Cohen Keeps Buying Acadia Pharmaceuticals, a Stock Down by Half This Year Jun 20 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 15.95 |
| Today’s open | 16.17 |
| Day’s range | 15.78 - 16.22 |
| Volume | 77,089 |
| Average volume (3 months) | 2,919,961 |
| Market cap | $2.4B |
Data as of 2:31pm ET, 06/22/2018
Growth & Valuation
| Earnings growth (last year) | -0.85% |
| Earnings growth (this year) | +28.92% |
| Earnings growth (next 5 years) | -68.62% |
| Revenue growth (last year) | +620.68% |
| P/E ratio | NM |
| Price/Sales | 29.56 |
| Price/Book | 7.10 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TAROTaro Pharmaceutical ... | -1.09 | -0.92% |
| ---- | ||
| AKRXAkorn Inc | +0.15 | +0.95% |
| VRXValeant Pharmaceutic... | -0.43 | -1.74% |
Data as of 2:30pm ET, 06/22/2018
Financials
| Next reporting date | August 7, 2018 |
| EPS forecast (this quarter) | -$0.46 |
| Annual revenue (last year) | $124.9M |
| Annual profit (last year) | -$289.4M |
| Net profit margin | -231.71% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Stephen R. Davis |
Executive VP, Chief Financial & Accounting Officer Todd S. Young |
Corporate headquarters San Diego, California |
Forecasts
